Surrozen (SRZN) Projected to Announce Earnings on Friday

Key Points

• Surrozen is expected to report Q3 2026 results before Friday’s market open, with analysts forecasting a loss of $1.10 per share and revenue of approximately $0.47 million. The earnings call is scheduled for 4:00 p.m. ET that day.
• The company’s previous quarter exceeded expectations, reporting a $0.41-per-share loss versus the projected $1.29 loss and generating $5.0 million in revenue against a $0.47 million estimate.
• Surrozen shares opened at $29.46, while analyst sentiment remains a consensus “Moderate Buy” with an average price target of $48.33, despite ratings ranging from Strong Buy to Sell.

Surrozen (NASDAQ:SRZN - Get Free Report) is projected to post its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Surrozen to post earnings of ($1.1039) per share and revenue of $0.47 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Surrozen (NASDAQ:SRZN - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.88. The business had revenue of $5.00 million during the quarter, compared to analysts' expectations of $0.47 million. On average, analysts expect Surrozen to post ($1.01) EPS for the current fiscal year and ($4.19) EPS for the next fiscal year.

Surrozen Price Performance

Shares of NASDAQ:SRZN opened at $29.46 on Friday. The firm has a 50 day moving average of $24.20 and a 200 day moving average of $24.92. Surrozen has a 52 week low of $11.39 and a 52 week high of $37.83.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SRZN. William Blair assumed coverage on Surrozen in a report on Thursday, August 20th. They issued an "outperform" rating and a $51.00 price target on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Surrozen in a research note on Thursday, October 15th. HC Wainwright reissued a "buy" rating and set a $54.00 price target (up from $44.00) on shares of Surrozen in a research report on Friday, September 25th. Finally, Zacks Research upgraded shares of Surrozen from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $48.33.

About Surrozen

Surrozen, Inc is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation.

The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.